EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Wells Fargo has recently initiated Exact Sciences Corp (EXAS) stock to Overweight rating, as announced on August 28, 2024, according to Finviz. Earlier, on June 27, 2024, Scotiabank had initiated the ...

Read Next: Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race Outlook: Exact Sciences sees fiscal year 2024 total revenue in a range of $2.73 billion ...

Exact Sciences Corporation EXAS reported a net loss ... Furthermore, the dismal outlook for the full year is discouraging for the stock. On a promising note, the top line improved year over ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in Exact Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns ...

Baird maintained an Outperform rating on Exact Sciences but reduced the stock's price target from $70.00 to $67.00. The adjustment came after the company reported third-quarter revenue that fell ...